本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
LONDON, Jan. 17, 2025 /PRNewswire/ -- IFS, the leading technology provider of enterprise cloud and Industrial AI software, has announced the winners of its 2024 Partner of the Year Awards during the IFS 2025 Sales Kickoff in London. The awards recognize the outstanding contributions of IFS's global partner community, acknowledging their critical role in driving innovation, growth, and success for customers across industries. Reflecting on the achievements of the past year, Max Roberts, Chief Operating Officer at IFS, shared: "This past year has been truly remarkable, marked by significant accomplishments, solid growth, and stronger relationships within our partner community. Thanks to the dedication and hard work of our partners, we've seen a 40% year-on-year increase in license revenue driven by partners and 34% growth in partner revenue in 2024 compared to the previous year. The commitment to innovation, excellence, and collaboration shown by our partners has been key to our success. Together, we are demonstrating the power of our partner-first strategy, delivering real value for our customers and paving the way for continued growth." To ensure a comprehensive evaluation, the Innovation Partner Award was assessed by a panel of industry analysts from IDC and Verdantix, who brought their expertise to the evaluation of a highly competitive pool of entries. 2024 Partner of the Year Award Winners Cloud Partner Award: Arcwide Global Growth Partner Award: Accenture Innovation Partner Award: PWC Regional Partner Award: NEC Customers' Choice Partner Award: Xitricron Outstanding Channel Deal Maker Award: 12 Guide Channel Sales Excellence Award: Hoist Technology Partner Award: Microsoft IFS Foundation Partner Award: Platned Global Channel Partner: InfoConsulting Global Partner: Accenture This year's awards highlight IFS's ongoing commitment to nurturing a thriving partner community. By staying focused on a partner-first strategy, IFS continues to empower partners to deliver innovative solutions, drive transformation, and help customers achieve success in their industries. The awards process was led by a global steering committee of IFS representatives who reviewed nominations for merit-based categories. This year's Customers' Choice Partner Award featured nominations submitted directly by IFS customers, showcasing the valuable contributions of the partner community. About IFS IFS is the world's leading provider of Industrial AI and enterprise software for businesses that make, service, and power our planet. Our technology enables businesses that manufacture goods, maintain complex assets, and manage service-focused operations to unlock the transformative potential of Industrial AI™ to enhance productivity, efficiency, and sustainability. IFS Cloud is a fully composable AI-powered platform, designed for ultimate flexibility and adaptability to our customers' specific requirements and business evolution. It spans the needs of Enterprise Resource Planning (ERP), Enterprise Asset Management (EAM), Supply Chain Management (SCM), and Field Service Management (FSM). IFS technology leverages AI, machine learning, real-time data, and analytics to empower our customers to make informed strategic decisions and excel at their Moment of Service™. Founded in 1983 by five university friends who pitched a tent outside our first customer's site to ensure they would be available 24/7 and the needs of the customer would come first, IFS has since grown into a global leader with over 7,000 employees in 80 countries. Guided by the core values of agility, customer-centricity, and trust, IFS is recognized worldwide for delivering value and supporting industry transformations. We are the most recommended supplier in our sector. Visit ifs.com to learn why. IFS Press Contacts:EUROPE / MEA / APJ: Adam GillbeIFS, Director of Corporate & Executive CommunicationsEmail: adam.gillbe@ifs.com NORTH AMERICA / LATAM: Mairi Morgan IFS, Director of Corporate & Executive Communications Email: mairi.morgan@ifs.com This information was brought to you by Cision http://news.cision.com https://news.cision.com/ifs/r/ifs-announces-2024-partner-of-the-year-awards-at-the-ifs-global-partner-summit-during-ifs-sales-kick,c4092919 The following files are available for download: https://news.cision.com/ifs/i/press-release-17th,c3369160 press release 17th
Travel industry leaders gathered in Abu Dhabi for Trip.com Group's Global Partner Summit, celebrating a year of strong growth marked by a 70% year-on-year increase in Asia-Pacific bookings. Trip.com Group announces a strategic partnership with summit host city Abu Dhabi's Department of Culture and Tourism to showcase the destination's global appeal ABU DHABI, UAE, Dec. 19, 2024 /PRNewswire/ -- Opportunities, collaboration, and future growth took centre stage at Trip.com Group's annual Global Partner Summit, where over 2,000 industry leaders, including representatives from accommodation providers, airlines, attractions and tour operators, tourism boards, and the media, gathered to envision the future of travel. With the theme 'A Shared Journey to a Better World', the summit was held at the Abu Dhabi National Exhibition Centre, and provided a forum for stakeholders to come together to celebrate the industry's resilience, reflect on its achievements, and chart a collective path towards future success. "In recent years, the travel industry has faced immense challenges. By working together, we have not only overcome these, but emerged stronger, and with renewed innovative vigour," said Jane Sun, CEO of Trip.com Group. "This year's summit celebrates the spirit of unity and collaboration that drives us to create new opportunities and underpins our collective efforts towards a brighter future. Together with our partners, we are paving the way for travel to inspire and connect, and making strides towards a better world." Celebrating Progress and Creating Opportunities The summit highlighted the remarkable progress made by the travel industry in 2024. Trip.com Group data indicates that hotel and flight bookings have grown by over 60% year-on-year, reflecting robust global demand. The Asia-Pacific region demonstrated particularly strong performance, with a more than 70% year-on-year increase in overall bookings, while international flight bookings across Asia almost doubled compared to last year's volumes. Trip.com Group has further solidified its leadership, including through partnerships with airlines such as Ryanair, Europe's largest airline, and has earned recognition from the International Air Transport Association (IATA) with its GoGlobal certification, the industry's gold standard. In the accommodation sector, Trip.com Group supports 1.7 million hotel partners worldwide, leveraging technology to drive growth, including through Trip.Best, its hotel review ranking system, which delivered an over 20% increase in traffic for participating properties. To further enhance the travel ecosystem and meet growing traveller demand for experiences, Trip.com Group is transforming the way attractions and activities are accessed and booked. The Open API Platform, based on the OCTO standard, streamlines connectivity for suppliers, eliminating the need for complex integrations and making it easier for customers to discover and book attractions, tours, and experiences. This innovation simplifies operations for partners while providing travellers with a seamless booking experience. Trip.Biz, the corporate travel arm of Trip.com Group, also showed strong global momentum. In the Asia-Pacific region, innovative solutions like the globally available Trip.Biz VCC payment system, as well as a 135% increase in hotel coverage, contributed to a 53% year-on-year growth in clients. These achievements reflect how Trip.com Group's commitments to collaboration and innovation are enhancing global travel ecosystems and driving growth across all sectors. Driving Sustainability and Innovation In line with its vision of building a better world through travel, Trip.com Group reaffirmed its commitment to sustainability with initiatives that promote eco-conscious travel and community development. For instance, the Trip.com Group Country Retreats Project supports local social and economic development through investments in high-end eco-tourism accommodation in rural regions. To date, the 34 retreats have boosted local economies, created sustainable employment opportunities, and set new benchmarks for eco-conscious tourism. The project was also recently recognised in the UN Global Compact's ESG 20 Report, highlighting Trip.com Group's pioneering role in advancing sustainable growth for the travel and tourism industry. Trip.com Group has made strides in promoting more sustainable travel practices, including the introduction of innovative travel products and carbon-saving solutions that reduced travel-related emissions by over 260,000 tons in 2024. Working with partners, Trip.com Group is also leading industry-wide action, including through its Low-Carbon Hotel Initiative, which encourages the integration of renewable energy solutions such as photovoltaic solar panels, saving costs and improving efficiency for participating hotels. Since November 2024, Trip.com has featured "Certified Sustainable" labels for properties certified by a GSTC-Accredited Certification Body, making it easier for travellers to identify and book eco-friendly options. "Creating positive, lasting value for customers, partners, communities, and the environment lies at the heart of our mission," said James Liang, Chairman of Trip.com Group. "From pioneering a family-friendly workplace, to promoting travel practices that support social and economic development, we are working with stakeholders worldwide to build a more resilient, connected, and sustainable future for travel." Forging Strategic Partnerships H.E. Saleh Mohamed Al Geziry, Director General of Tourism, Department of Culture and Tourism - Abu Dhabi, with Trip.com Group CEO Jane Sun At the event, Trip.com Group also announced a strategic partnership with the Department of Culture and Tourism – Abu Dhabi (DCT) for 2025. Through the collaboration, both sides will promote Abu Dhabi as a premier global travel destination and encourage extended stays for international visitors. Through Trip.com Group's channels, the initiative will connect travellers with Abu Dhabi's attractions, resort experiences, and seasonal highlights, as well as offer curated group tours and one-day itineraries that showcase the region's unique culture and natural beauty. Abdulla Yousuf, Director of International Operations at DCT Abu Dhabi, said: "We are pleased to partner with Trip.com Group, a leading global travel platform, to enhance Abu Dhabi's presence among travellers worldwide. This collaboration underscores our commitment to fostering strategic partnerships that expand our global reach and connect visitors to Abu Dhabi's diverse and world-class offerings. With Trip.com Group's extensive influence across key international markets we aim to create meaningful value for all stakeholders and showcase Abu Dhabi as a premier destination for culture, adventure, and year-round experiences." Travel to the Middle East has seen a significant surge. According to Trip.com Group data, international flight bookings to the region for the first eleven months of 2024 rose by over 70% compared to the same period in 2023, and were more than 430% higher than in the same period in 2019. The top source markets were China, the UK, and Germany, highlighting the region's broad appeal. The partnership with DCT will build on this momentum to showcase Abu Dhabi's unique offerings to global audiences. Looking Ahead As the travel industry looks to the future, Trip.com Group remains committed to its mission of leading with values of innovation, sustainability, and collaboration, striving to secure opportunities for sustainable growth, and working towards a more connected and better world for all. About Trip.com Group Trip.com Group is a leading global travel service provider comprising of Trip.com, Ctrip, Skyscanner, and Qunar. Across its platforms, Trip.com Group helps travellers around the world make informed and cost-effective bookings for travel products and services and enables partners to connect their offerings with users through the aggregation of comprehensive travel-related content and resources, and an advanced transaction platform consisting of apps, websites and 24/7 customer service centres. Founded in 1999 and listed on NASDAQ in 2003 and HKEX in 2021, Trip.com Group has become one of the best-known travel groups in the world, with the mission "to pursue the perfect trip for a better world". Find out more about Trip.com Group here: group.trip.com. Follow us on: X, Facebook, LinkedIn, and YouTube.
SINGAPORE, Oct. 24, 2023 /PRNewswire/ -- Leading travel service provider Trip.com Group held its Global Partner Summit in Singapore, inviting guests from across the travel industry, including accommodation, airline and destination marketing partners. More than 2,000 partners and media attended the event held at the Resorts World Singapore – Convention Centre. James Liang, Co-founder and Chairman of Trip.com Group, delivers opening speech at the 2023 Global Partner Summit James Liang, Co-Founder and Chairman of Trip.com Group, explained why travel is unique from a multifaceted perspective. "Psychologically, it fulfils a high level of need which is not easily saturated. In economic terms, it is a long-term, high-growth industry. At the social level, it promotes human understanding, enhances communication and brings peace and inclusiveness. Philosophically, tourism helps promote human innovation, thus pursuing the long-term prosperity of human civilisation. "At Trip.com Group, we have made it our mission to provide the best travel experience possible. We will explore AI innovation, travel content marketing, and sustainable practices to enhance every aspect of the user experience while preserving our planet and community." As the tourism industry gradually recovers and grows, Trip.com Group has taken a significant step towards its "Local Focus, Global Vision" strategy by holding its Global Partner Conference abroad for the first time. This move signifies the ambitious outlook for the inbound and outbound tourism industry and reaffirms the company's commitment to enhancing global partner growth. Jane Sun, CEO of Trip.com Group, delivers keynote speech to partners at the Global Partner Summit Speaking at the conference, Jane Sun, CEO of Trip.com Group, recapped the vigorous recovery of its businesses and reflected on the potential for further growth. "Guided by our strategy, multi-dimensional innovations in content marketing and AI-driven products, we have strengthened the Group's business, accelerating our recovery and bringing forward new growth drivers. "Our approach continues to pay dividends, with the number of Trip.com bookings doubling this year compared to 2019 and the number of flight reservations for our EU partners increasing sevenfold." Notably, various businesses have achieved restorative growth, with domestic hotel reservation volumes increasing by an average of 60% among Trip.com Group partner hotels. The growth extended to global scenic attraction tickets and reservations on Trip.com. The domestic group tours sector also experienced an increase in Gross Merchandise Value (GMV) with a 53.6% surge compared to the same period in 2019, highlighting the overall resurgence of the industry. Trip.com Group's innovative marketing strategies have led to a threefold increase in new customers and a 263% spike in product sales in the first three quarters of the year. They have been a catalyst for remarkable growth, such as a 54 times increase in new customers for air tickets. Diverse product offerings, including multi-scenic attractions tickets, as well as concert tickets with hotel packages, generated an astounding 188-fold increase in hotel reservations in recent months. Dedicated to supporting and enhancing the communities it serves, Trip.com Group has taken significant steps to incorporate sustainable travel products into its various business lines, including flights, car rental, and corporate travel. Over 16 million people have chosen these sustainable travel options, favouring the company's low-carbon products. As part of its ongoing commitment to promote a sustainable travel industry, Trip.com Group launched its Low-Carbon Hotel standard initiative, which aims to encourage eco-friendly practices, and facilitate a shift towards a more sustainable travel ecosystem by collaborating with hotel partners. Trip.com Group has engaged with nearly 1,000 hotel partners in this transformative project. With its global reach, diversified supply chain, and strengthened technological capabilities, Trip.com Group is distinctively positioned to bolster and promote regional and local destinations to eager travellers worldwide. Bo Sun, CMO of Trip.com Group, presents on partnership cooperation and expanding content marketing ecosystem Bo Sun, CMO of Trip.com Group, said, "Trip.com Group continues to deepen strategic cooperation with our partners in Singapore, leveraging our position as a leading travel service provider to unlock new opportunities and expanding partner reach to our international customers. "With our global supply chain, advanced and innovative technology, and extensive reach, we are uniquely positioned to showcase regional and local destinations to travellers worldwide, and help bring global travellers to Singapore." Data shows that travel-related products to Singapore have become increasingly popular in recent months. Resort World Singapore Group experienced an 85% QoQ increase in UV search for Q2; in Q3, there was another 33% increase. During the recent Golden Week holiday, Singapore hotel bookings increased by 370% compared to 2022. Bo Sun expressed his gratitude for the unwavering support seen over the years, saying, "This is our first global partner summit held overseas, and we would like to express our sincere gratitude to the Singapore Tourism Board and other stakeholders for their support and continued cooperation. "Singapore is one of our top-ranked destinations among our customers and the International Headquarters of Trip.com. Going forward, we aim to enhance our partnerships, and attract more travellers for a unique experience in this beautiful country, whether for business, leisure, or bleisure trips. At the same time, we also look forward to welcoming Singaporean travellers to the various destinations." --- END --- About Trip.com Group Trip.com Group is a leading global travel service provider comprising of Trip.com, Ctrip, Skyscanner, and Qunar. Across its platforms, Trip.com Group helps travellers around the world make informed and cost-effective bookings for travel products and services and enables partners to connect their offerings with users through the aggregation of comprehensive travel-related content and resources, and an advanced transaction platform consisting of apps, websites and 24/7 customer service centres. Founded in 1999 and listed on NASDAQ in 2003 and HKEX in 2021, Trip.com Group has become one of the best-known travel groups in the world, with the mission "to pursue the perfect trip for a better world". Find out more about Trip.com Group here. Follow us on Twitter, Facebook, LinkedIn, and YouTube.
HONG KONG, May 4, 2023 /PRNewswire/ -- IPLOOK Technologies, the global vendor of industry-leading end-to-end mobile core network solutions, has successfully hosted a global partner summit in Bangkok, Thailand from April 27th to 28th. With the theme "More connections, more changes", the summit was sponsored by Links field, NEWARE, Harvilon, Ribbon and Junosoft, to empower ecosystem partners for insightful visions and more opportunities. "Glad to gather IPLOOK's partners for unlocking new opportunities. Cooperation would bring us win-win outcomes in the fast-developing telecom industry," said Tom Lyu, CEO of IPLOOK, indicating start of the summit. During the summit, speakers made keynote speeches about heated topics in the telecom industry. All attendees began an exhaustive discussion. The summit was streamed live globally on YouTube. Review wonderful moments here: Day 1 and Day 2. Jarod Wang, VP-Sales&Service of IPLOOK: IPLOOK Connects Everything and Everywhere Patrick SZETO, BD/Cofounder at Links Field: Complement each other Sinead Wang, Senior Marketing Manager at NEWARE: Reliable telecom solutions for innovative connectivity operators Jacky Xie, Sales Director at Harvilon: Harvilon 5G Terminals Empower Operator's FWA Deployment Owen Ouyang, Region Director of Africa at IPLOOK: MVNO Promoting The Connection Frank Li, Head of IPLOOK Istanbul branch: Private network Ben Ling, Sales Director at Ribbon: Empower Ecosystem Partners to Win Together Johnny Jiang, VP/Sales Director at Junosoft: New Challenger in B/OSS Babacar Niang, Director of BD in Africa at IPLOOK: The Benefits of Converge Core This Summit is the first gathering held by IPLOOK in 2023, which is an opportunity for key partners to come together and enhance connections for positive changes. IPLOOK has played an active role in the participation of global industry events. Through this summit, IPLOOK enhances the determination to take bold steps towards the global market with our industry partners, providing mobile core network solutions to more customers. In June, IPLOOK will participate in MVNOs world congress held in Amsterdam and wish to meet with new and existing partners at booth 23. About IPLOOK IPLOOK Technologies is a leading vendor of 4G/5G networking solutions, offering a complete line of products for MNO, MVNO, service providers and enterprise private networks to fulfill the growing connectivity needs. More info: www.iplook.com Follow IPLOOK on LinkedIn @IPLOOK Technologies CONTACT: info@iplook.com
HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy compared to pembrolizumab monotherapy in the first-line treatment of PD-L1 positive (PD-L1 TPS ≥1%) locally advanced or metastatic non-small cell lung cancer (NSCLC) have been published in The Lancet. The Lancet is a prestigious international medical journal, and the publication of the HARMONi-2 study results in The Lancet is a strong recognition by the academic community to the breakthrough clinical potential of ivonescimab. Previously, clinical research on using ivonescimab for the treatment of various malignant tumors has been published in renowned international medical journals such as JAMA, Journal of Thoracic Oncology, eClinical Medicine (a sub-journal of The Lancet), and Drugs. At the 2024 World Conference on Lung Cancer (WCLC), the results of the HARMONi-2 study were presented as an oral report by the principal investigator of the study, Professor Zhou Caicun, a renowned oncology expert who is the President-Elect of IASLC, and the director of the Department of Oncology at the Shanghai East Hospital, Tongji University. The HARMONi-2 study demonstrated that in the intent-to-treat population, ivonescimab monotherapy significantly extended progression-free survival (PFS) compared to pembrolizumab monotherapy, reducing the risk of disease progression by 49% (PFS HR 0.51, P<0.0001). Subgroup analyses revealed that regardless of patients' age, gender, ECOG performance status, PD-L1 expression, histological type, or the presence of liver or brain metastases, the ivonescimab group showed significant improvement in efficacy compared to the pembrolizumab group. The ivonescimab HARMONi-2 study is the world's first randomized, double-blind, controlled Phase III clinical trial to achieve significantly positive results compared to pembrolizumab. Based on these promising results, the sNDA for ivonescimab monotherapy as a first-line treatment for PD-L1 positive NSCLC is under review with priority status in China. Ivonescimab in combination with chemotherapy for EGFR-TKI-resistant non-squamous NSCLC, has already been approved and included in the 2024 China National Reimbursement Drug List. The growing body of clinical evidence from multiple Phase II and Phase III studies continues to validate ivonescimab's efficacy benefit and safety profile. These results are often published in major international conferences and in top-tier journals, providing oncologists strong scientific basis for treatment decisions. Akeso has strategically positioned ivonescimab within a comprehensive development plan, aiming to reshape the landscape of cancer immunotherapy and establish a new global standard of care. Ivonescimab, in combination with chemotherapy, has been approved in China for the treatment of EGFR-TKI-resistant, non-squamous NSCLC. The New Drug Application (sNDA) for ivonescimab monotherapy as a first-line treatment for PD-L1-positive NSCLC (in comparison to pembrolizumab) is currently under review and has been granted priority status in China. Three international multicenter Phase III clinical trials, led by our partner Summit Therapeutics, are progressing efficiently or are being initiated: The HARMONi study, an international multicenter Phase III clinical trial evaluating ivonescimab in combination with chemotherapy for non-squamous NSCLC with progression after third-generation EGFR-TKI treatment, has had patient enrollment completed and has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA), The HARMONi-3 study, an international multicenter Phase III clinical trial comparing ivonescimab combined with chemotherapy as first-line treatment for both squamous and non-squamous NSCLC (versus pembrolizumab combined with chemotherapy), The HARMONi-7 study, an international multicenter Phase III clinical trial evaluating ivonescimab monotherapy as first-line treatment for PD-L1 high-expressing NSCLC (versus pembrolizumab). Several Phase III clinical trials are progressing efficiently or are being initiated in China, including: Ivonescimab combined with chemotherapy as first-line treatment for squamous NSCLC (vs. tislelizumab combined with chemotherapy, HARMONi-6/AK112-306), Ivonescimab combined with chemotherapy as first-line treatment for biliary tract cancer (vs. durvalumab combined with chemotherapy, HARMONi-GI1/AK112-309), Ivonescimab combined with AK117 (CD47) as first-line treatment for PD-L1 positive head and neck squamous cell carcinoma (vs. pembrolizumab, SOLO-10/AK117-302), First-line treatment for triple-negative breast cancer (HARMONi-BC1/AK112-308).
HONG KONG, Feb. 21, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of ivonescimab in combination with chemotherapy for first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) (HARMONi-BC1/AK112-308). Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody independently developed by the company. HARMONi-BC1/AK112-308 study is led by Professor Xu Binghe, a renowned breast cancer expert and academician of the Chinese Academy of Engineering, from the Cancer Hospital of the Chinese Academy of Medical Sciences. Preliminary efficacy data presented at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting demonstrated that ivonescimab combined with chemotherapy showed significant therapeutic efficacy and also exhibited a favorable safety profile, underscoring its clinical potential for the treatment of locally advanced or metastatic TNBC. Akeso has strategically positioned ivonescimab within a comprehensive development plan, aiming to reshape the landscape of cancer immunotherapy and establish a new global standard of care. Ivonescimab, in combination with chemotherapy, has been approved in China for the treatment of EGFR-TKI-resistant, non-squamous NSCLC. The New Drug Application (sNDA) for ivonescimab monotherapy as a first-line treatment for PD-L1-positive NSCLC (in comparison to pembrolizumab) is currently under review and has been granted priority status in China. Three international multicenter Phase III clinical trials, led by our partner Summit Therapeutics, are progressing efficiently or are being initiated: The HARMONi study, an international multicenter Phase III clinical trial evaluating ivonescimab in combination with chemotherapy for non-squamous NSCLC with progression after third-generation EGFR-TKI treatment, has had patient enrollment completed and has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA), The HARMONi-3 study, an international multicenter Phase III clinical trial comparing ivonescimab combined with chemotherapy as first-line treatment for both squamous and non-squamous NSCLC (versus pembrolizumab combined with chemotherapy), The HARMONi-7 study, an international multicenter Phase III clinical trial evaluating ivonescimab monotherapy as first-line treatment for PD-L1 high-expressing NSCLC (versus pembrolizumab). Several Phase III clinical trials are progressing efficiently or are being initiated in China, including: Ivonescimab combined with chemotherapy as first-line treatment for squamous NSCLC (vs. tislelizumab combined with chemotherapy, HARMONi-6/AK112-306), Ivonescimab combined with chemotherapy as first-line treatment for biliary tract cancer (vs. durvalumab combined with chemotherapy, HARMONi-GI1/AK112-309), Ivonescimab combined with AK117 (CD47) as first-line treatment for PD-L1 positive head and neck squamous cell carcinoma (vs. pembrolizumab, SOLO-10/AK117-302), First-line treatment for pancreatic cancer (HARMONi-GI2/AK112-310), First-line treatment for triple-negative breast cancer (HARMONi-BC1/AK112-308). About AkesoAkeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 22 candidates have entered clinical trials (including 11 bispecific/multispecific antibodies and bispecific antibody-drug conjugates). Additionally, 5 new drugs are commercially available, and 5 new drugs across 7 indications are currently under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin, and X (formerly Twitter).
Partner Summit
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
